Coherus BioSciences Dirección

Dirección controles de criterios 2/4

El CEO de Coherus BioSciences' es Denny Lanfear , nombrado en Sep 2010, tiene una permanencia de 13.58 años. compensación anual total es $5.90M, compuesta por 16.7% salario y 83.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.01% de las acciones de la empresa, por valor de €2.15M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 2.8 años, respectivamente.

Información clave

Denny Lanfear

Chief Executive Officer (CEO)

US$5.9m

Compensación total

Porcentaje del salario del CEO	16.7%
Permanencia del CEO	13.8yrs
Participación del CEO	1.0%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Denny Lanfear en comparación con los beneficios de Coherus BioSciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$59m
Dec 31 2023	US$6m	US$983k	-US$238m
Sep 30 2023	n/a	n/a	-US$217m
Jun 30 2023	n/a	n/a	-US$264m
Mar 31 2023	n/a	n/a	-US$271m
Dec 31 2022	US$7m	US$945k	-US$292m
Sep 30 2022	n/a	n/a	-US$279m
Jun 30 2022	n/a	n/a	-US$230m
Mar 31 2022	n/a	n/a	-US$210m
Dec 31 2021	US$9m	US$885k	-US$287m
Sep 30 2021	n/a	n/a	-US$232m
Jun 30 2021	n/a	n/a	-US$165m
Mar 31 2021	n/a	n/a	-US$76m
Dec 31 2020	US$7m	US$857k	US$132m
Sep 30 2020	n/a	n/a	US$162m
Jun 30 2020	n/a	n/a	US$181m
Mar 31 2020	n/a	n/a	US$145m
Dec 31 2019	US$5m	US$751k	US$90m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$118m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$4m	US$702k	-US$209m
Sep 30 2018	n/a	n/a	-US$196m
Jun 30 2018	n/a	n/a	-US$196m
Mar 31 2018	n/a	n/a	-US$208m
Dec 31 2017	US$3m	US$656k	-US$238m

Compensación vs. Mercado: La compensación total de Denny($USD5.90M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.27K).

Compensación vs. Ingresos: La compensación de Denny ha sido consistente con los resultados de la empresa en el último año.

CEO

Denny Lanfear (69 yo)

13.8yrs

Permanencia

US$5,897,924

Compensación

Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dennis Lanfear	Chairman	13.8yrs	US$5.90m	0.99% $ 1.8m
Bryan McMichael	Interim CFO	1.8yrs	US$1.07m	0.023% $ 40.9k
Paul Reider	Chief Commercial Officer	3.4yrs	US$1.93m	0.071% $ 126.1k
Richard Hameister	Chief Technical Officer	2.4yrs	sin datos	sin datos
Jami Taylor	Vice President of Investor Relations	no data	sin datos	sin datos
Andy Rittenberg	Executive Vice President of General Counsel	less than a year	sin datos	sin datos
Cheston Turbyfill	Vice President of Communications	no data	sin datos	sin datos
Scott Saywell	Executive Vice President of Corporate Development	1.4yrs	sin datos	sin datos
Rebecca Sunshine	Chief Human Resources Officer	no data	sin datos	sin datos
Michael Chen	Senior Vice President of Commercial Analytics & Trade	no data	sin datos	sin datos
Theresa Lavallee	Chief Development Officer & Chairman of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Rosh Dias	Chief Medical Officer	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 8C5 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dennis Lanfear	Chairman	13.8yrs	US$5.90m	0.99% $ 1.8m
Theresa Lavallee	Chief Development Officer & Chairman of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Mats Wahlstrom	Lead Independent Director	12.4yrs	US$228.69k	0.087% $ 155.1k
Mark Stolper	Independent Director	3.4yrs	US$198.69k	0.0077% $ 13.6k
Ali Satvat	Independent Director	10.1yrs	US$65.00k	0% $ 0
Lee Newcomer	Independent Director	2.3yrs	US$186.19k	0% $ 0
James Daly	Member of Strategic Advisory Board	less than a year	sin datos	sin datos
Charles Newton	Independent Director	2.1yrs	US$188.69k	0% $ 0
Jill O'Donnell-Tormey	Independent Director	2.1yrs	US$183.69k	0% $ 0
Kimberly Tzoumakas	Independent Director	3.9yrs	US$193.69k	0% $ 0
Carl Ware	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Thomas Graeber	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos

2.9yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 8C5 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Coherus BioSciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

High number of new and inexperienced directors

Recent updates

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings released: EPS: US$0.91 (vs US$0.95 loss in 1Q 2023)

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.76 loss in FY 2022)

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$1.12 loss in 3Q 2022)

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Second quarter 2023 earnings released: US$0.49 loss per share (vs US$0.65 loss in 2Q 2022)

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.95 loss per share (vs US$1.24 loss in 1Q 2022)

Full year 2022 earnings released: US$3.76 loss per share (vs US$3.81 loss in FY 2021)

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$1.12 loss per share (vs US$0.49 loss in 3Q 2021)

Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022

Coherus BioSciences, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.40 loss in 2Q 2021)

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors

First quarter 2022 earnings released: US$1.24 loss per share (vs US$2.38 loss in 1Q 2021)

Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee

Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 17, 2022

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Coherus BioSciences, Inc. Appoints Paul Reider as Chief Commercial Officer

Coherus BioSciences, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Coherus BioSciences, Inc. Announces Management Changes

Coherus BioSciences, Inc. Announces U.S. FDA Approval of YUSIMRY

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Positive Interim Overall Survival Results of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.39 profit in 3Q 2020)

Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma